Pherecydes Pharma Logo

Pherecydes Pharma

Develops precision phage therapy to treat resistant bacterial infections.

ALPHE | PA

Overview

Corporate Details

ISIN(s):
FR0011651694
LEI:
894500LYT3UUN58X3I68
Country:
France
Address:
22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Pherecydes Pharma is a biotechnology company that specializes in developing treatments for resistant bacterial infections. The company pioneers precision phage therapy, an approach that uses bacteriophage viruses (phages) to specifically target and combat harmful bacteria. This personalized therapeutic strategy is designed to treat severe and complicated infections that are unresponsive to conventional antibiotics. Founded in 2006, the company focuses on creating a portfolio of phages effective against critical bacterial pathogens. In June 2023, Pherecydes Pharma merged with Erytech Pharma to become Phaxiam Therapeutics, continuing its work in the fight against antimicrobial resistance.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-23 20:45
AGM Information
Informations privilégiées / Autres communiqués
French 214.3 KB
2023-06-23 20:45
AGM Information
Inside Information / Other news releases
English 213.8 KB
2023-06-14 20:00
Legal Proceedings Report
Inside Information / Other news releases
English 197.1 KB
2023-06-14 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 200.6 KB
2023-06-08 07:30
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 297.3 KB
2023-06-08 07:30
Regulatory Filings
Inside Information / Other news releases
English 269.4 KB
2023-06-05 08:00
Legal Proceedings Report
Inside Information / Other news releases
English 198.4 KB
2023-06-05 08:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.1 KB
2023-06-02 20:00
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 152.4 KB
2023-05-23 23:43
M&A Activity
News releases during takeover bids / Takeover bids Other news releases
English 191.8 KB
2023-05-23 23:43
Registration Form
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 184.9 KB
2023-05-16 07:00
M&A Activity
Inside Information / Other news releases
English 224.2 KB
2023-05-16 07:00
M&A Activity
Informations privilégiées / Autres communiqués
French 216.3 KB
2023-05-11 18:00
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 200.6 KB
2023-04-27 18:00
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 195.2 KB

Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pherecydes Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea
354200
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France
COX
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive electric field therapy to disrupt and treat aggressive solid tumor cancers.
United States of America
NVCR
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.